SANTA CLARA, Calif., Nov. 30 /PRNewswire/ -- Applied Imaging Corp.
(Nasdaq: AICX), today announced the signing of a multi-year distribution
agreement for its QUIPS(R) range of cytogenetic instruments with Milan based
Olympus Italia S.r.l., a leading supplier of medical and laboratory equipment
in Italy.  Olympus Italia markets an extensive range of products for optical
microscopy and medical imaging applications that complement Applied Imaging's
cytogenetic analysis systems.
    "Italy represents a critical part of the European cytogenetic market, and
we are delighted to have partnered with Olympus Italia, given their proven
expertise in sales and service in the field," said Jack Goldstein, Chairman
and CEO of Applied Imaging.  "As the exclusive distributor of our QUIPS
cytogenetic analysis systems, we believe that Olympus, through the use of
dedicated resources, will significantly contribute to the future top line
growth of Applied Imaging."
    Olympus Italia recently signed an exclusive agreement with Vysis for the
distribution of fluorescent DNA probe kits which are used with Applied
Imaging's cytogenetic workstations.  As a result of this agreement with
Applied Imaging, Olympus Italy will become supplier of the most comprehensive
line in cytogenetic applications and products in the Italian market.

    About Olympus
    Olympus Italia S.r.l. has achieved a recognized position of strength in
the Italian scientific and diagnostics market as a result of it successes in
clinical chemistry, electrophoresis and immunohaematology.  It also has an
excellent reputation in the Cytogenetics market through its advanced line of
microscope products.  Olympus Italia has a first-class sales and service
organization backed up by an outstanding customer support structure.

    About Applied Imaging Corp.
    Applied Imaging Corporation, based in Santa Clara, Calif., develops,
manufactures, and markets automated clinical analysis systems used by
laboratories for cancer and prenatal genetics.  The Company markets its
products worldwide and has more than 1600 instruments at 800 customer sites in
over 35 countries.  Applied Imaging is a publicly traded company listed on the
Nasdaq Stock Market under the Symbol AICX.

    This press release contains forward looking statements as defined in the
Private Securities Litigation Reform Act of 1995, regarding, among other
matters, the Company's future financial performance.  Forward looking
statements address matters that are subject to a number of risks and
uncertainties.  Actual results could differ materially from those projected in
the forward-looking statement as a result of a number of factors including the
failure of the Company to successfully develop and commercialize its
micrometastasis or cytogenetic instrument businesses, and other such factors
as set forth in the Company's form 10K for the year ended December 31, 1998 as
filed with the Securities and Exchange Commission.
    For additional information on Applied Imaging via fax, please dial
1-800-PRO-INFO, (732-544-2850 outside of the U.S.), code AICX.

Link to this page: